• ASBMB 2016 Annual Meeting

Cell Signaling, Kinase, and Chemotherapy

Follow the conversation on Twitter: #cellsignal
 
Theme Organizers: Dan Leahy, Johns Hopkins Univ. Sch. of Med. and Susan Taylor, Univ. of California, San Diego   
 
The most up-to-date program information, view abstracts and plan your itinerary, download the EB2016 app or view online here: http://app.core-apps.com/eb2016
  

Sunday, April 3, 2016
San Diego Convention Center, Room 6E
9:45 am - 12:00 pm
Allosteric Control of Kinase Activity

Session Chair: Susan Taylor, Univ. of California, San Diego

9:45                        Chair’s Introduction.

9:50    102.1          Dimer Induced Regulation of Protein Kinase Function. F. Sicheri. Lunenfeld-Tanenbaum Res. Inst., Mount Sinai Hosp., Toronto.

10:15                      Phosphorylation  of  Secreted  Proteins   by  a New Family of Kinases. V.S. Tagliabracci, S. Wiley, J.Dixon. Univ. of Texas Southwestern and UCSD. (633.7)

10:30   102.2         HowEGF and InsulinActivate Their Receptors. D. Leahy. Johns Hopkins Univ. Sch. of Med.

10:55                      Designing Allosteric Switches of Kinases. N.V. Dokholyan, O. Dagliyan, K. Hahn. Univ. of North Carolina at Chapel Hill. (633.6)

11:10                      Protein   Dynamics   Defines  Allostery  in  the Conserved EPK Core. L.G. Ahuja, A.P. Kornev, C. McClendon, G.Veglia, S.Taylor. UCSD and Univ. of Minnesota, Minneapolis. (856.10)

11:25   102.3        Signaling   in   the   Catalytic   Subunit   of   Protein Kinase A via Hydrophobic Motifs. G. Veglia. Univ. of Minnesota, Minneapolis.

11:50                      Discussion.


Monday, April 4, 2016
San Diego Convention Center, Room 6E
4:00 pm - 6:15 pm
Signaling in Time and Space 

Session Chair: Dan Leahy, Johns Hopkins Univ. Sch. of Med. 

4:00                        Chair’s Introduction.

4:05     256.1         Endocytosis Separates EGF Receptors from Endogenous Fluorescently Labeled HRas and Prevents Receptor Signaling to MAP Kinases in Endosomes. A. Sorkin, I.Pinilla-Macua. Univ. of Pittsburgh.

4:30                        Super-Resolution Imaging of the  HER Family of Receptor TyrosineKinases. B. van Lengerich, E. Puchner, B. Huang, N. Jura. UCSF and Univ. of Minnesota, Minneapolis. (857.4)

4:45     256.2         New Mode of EGF Receptor Transactivation: Regulated Ligand Delivery. R.J. Coffey, Z. Cao, B. Singh. Vanderbilt Univ. Med. Ctr. and DVA Nashville, TN.

5:10                         Three-Dimensional    Quantification    of    the Spatiotemporal Co-evolution of Vascular and Neuronal Networks within Intact Eyes. J. Singh, D. Shepherd, G. Seedorf, J. Brzezinski  Univ. of Colorado Denver and Univ.  of Colorado Sch. of Med., Aurora. (857.1)

5:25                         An    Optogenetic    Toolkit    for   Spatial   and Temporal  Control  of  the  cAMP  Dependent  Protein  Kinase. C.P. OBanion, R. Hughes,M. Priestman, D. Lawrence. Univ. of North Carolina Chapel Hill. (857.2)

5:40     256.3          Spatial  Correlation  of  Constitutive  HER2  Activities with Cell Membrane Deformation. I. Chung. HHMI, Ashburn, VA and Genentech, South San Francisco.

6:05                         Discussion.


Tuesday, April 5, 2016
San Diego Convention Center, Room 6E
9:45 am - 12:00 pm
Targeted Therapies 

Session Chair: Frank Sicheri, Lunenfeld-Tanenbaum Research Institute of Sinai Health System 

9:45        Chair's introduction.
 
9:50    382.1         Kinases as Molecular Switches: Catalytic and Non-catalytic Functions of BRAF Reveal Novel Insights into Oncogenic Activation. S. Malek, S. Foster, D.Whalen, A. Ozen, J. Haling, J. Sudhamsu, I. Yen,  J. Yin, G. Hatzivassiliou, A. Shaw, C. Yu, C. Eigenbrot, G. Manning, N. Skelton, S. Hymowitz. Genentech.
 
10:15                     ProKinO: A Unified  Resource  for  Mining the Cancer Kinome. N. Kannan. Univ. of Georgia. (1107.4)
 
10:30     382.2     Targeting Tumors Driven by VHL  or  IDH  Mutations. W. Kaelin. Dana-Farber Cancer Inst. and Brigham and Women’s Hosp., Harvard Med. Sch., HHMI.
 
10:55                     Covalent Inhibition of ERK Docking Interactions. T.S. Kaoud, W.H. Johnson, A. Piserchio, N.D. Ebelt, M. Warthaka, M. Cano, R. Sammons, Q. Wang, P. Ren, R. Ghose, K.N. Dalby. Univ. of Texas at Austin, Fac. of Pharm., Minia Univ., Egypt and City Col. of New York. (856.11)
 
11:10                      Leads to Acquired HER-Targeted Therapy Resistance That Can Be Reversed by the Irreversible HER1/2 Inhibitor Afatinib. X. Xu, A. Nardone, H. Hu, L. Qin, S. Nanda, T.  Mitchell, M. Shea, L. Heiser, N. Wang, K. Covington, E. Chen, A. Renwick, T. Wang, C. De Angelis, A. Contreras, C. Gutierrez, S. Fuqua, G. Chamness, C. Shaw, D. Wheeler, J. Gray, S. Hilsenbeck, M. Rimawi, K. Osborne, R. Schiff. Baylor Col. of Med., Oregon Hlth. & Sci. Univ. and MD Anderson Cancer Ctr., Houston. (1107.5)
 
11:25      382.3      Disrupting  Adaptive   Bypass   Pathways  Activated by Targeted Kinase Inhibitors. G.L. Johnson. Univ. of North Carolina Sch. of Med.
 
11:50        Discussion.


Wednesday, April 6, 2016
San Diego Convention Center, Room 6E
2:15 pm - 4:30 pm
Tumor Suppressors/Tumor Drivers
Session Chair: Shiva Malek, Genentech  

2:15                         Chair’s Introduction.

2:20      510.1         Reversing the Paradigm: Protein Kinase C as  a Tumor Suppressor. A. Newton. UCSD.

2:45                         Ceramide  Is  a  Key  Factor  ThatRegulates the Crosstalk between TGF-β and Sonic Hedgehog Signaling at the Basal Cilia to Control Cell Migration and Tumor Metastasis. S.Gencer, N. Oleinik, M. Dany, B. Ogretmen. Med. Univ. of South Carolina and Uskudar Univ. and Abdullah Gul Univ., Turkey. (1108.2)

3:00      510.2         DNAJB1-PKRACA    A  Novel   PKA   Fusion Protein That Drives Fibrolamellar Hepatocellular   Carcinoma.S. Simon. The Rockefeller Univ.

3:25                          HER2+ Breast Cancer Metastasis Mediated by E2F2 Copy Number Changes. E. Andrechek. Michigan State Univ. (1108.3)

3:40                          Exosomes  Secreted  by Inflammatory Cytokine Stimulated Glioma Cells Carry a Repertoire of Proteins Which Influence Progression of Glioblastoma Multiforme. R.A. Kore, E.C. Abraham, R.J. Griffin. Univ. of Arkansas for Med. Sci. (1108.16)

3:55      510.3         Dysfunctional PKA Drives Diverse Disease Phenotypes. S.S. Taylor, J. del Rio, J. Bruystens, G. Veglia, E. Stefan, R. Ilouz, P. Zhang. UCSD, Univ. of Minnesota, Minneapolis and Univ. of Innsbruck, Austria.

4:20                         Discussion.